VIDRAFT Pits Claude Against GPT-4 in Open AI Drug Discovery Challenge for Malaria and TB
Korean AI startup VIDRAFT has launched an open drug discovery competition on Hugging Face, inviting developers and researchers to use any frontier AI model to propose candidate molecules targeting malaria and tuberculosis. The challenge is generative rather than predictive, scoring submissions on a composite metric covering drug efficacy, toxicity, target-binding affinity, and ADME properties. Early data from the first three days, first reported by Jeon Ja Sinmun on August 18, 2026, shows Claude-family submissions outperforming OpenAI-family ones on the malaria track with scores of 43.7 versus 31.7, with the same ranking observed on the tuberculosis track. Over 2,000 candidate molecules were submitted within the opening three days, with eligible tools including Claude, ChatGPT, Gemini, DeepSeek, and custom AI systems. VIDRAFT chose malaria and TB as initial targets due to their heavy global disease burden and a well-documented lack of private pharmaceutical investment in these neglected areas.
This is an AI-generated summary. ShortSingh links to the original source for the complete article.
Discussion (0)
Log in to join the discussion and vote.
Log in